Cargando…

Prevalence of Clinical Spectrum of Cutaneous Adverse Drug Reactions in Patients Presenting at a Tertiary Care Hospital in Pakistan

Introduction: Cutaneous adverse drug reactions (CADRs) are the most common adverse drug reactions reported in the literature. CADRs have resulted in disabling infirmities during hospitalization and complications following outdoor drug therapy. The pattern of CADRs and the responsible drugs usually c...

Descripción completa

Detalles Bibliográficos
Autores principales: Hina, Ayesha, Masood, Sadia, Jamil, Sajjad, Tabassum, Saadia, Jalil, Palwasha, Ghulam, Unzela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8133508/
https://www.ncbi.nlm.nih.gov/pubmed/34026384
http://dx.doi.org/10.7759/cureus.14568
_version_ 1783695086558642176
author Hina, Ayesha
Masood, Sadia
Jamil, Sajjad
Tabassum, Saadia
Jalil, Palwasha
Ghulam, Unzela
author_facet Hina, Ayesha
Masood, Sadia
Jamil, Sajjad
Tabassum, Saadia
Jalil, Palwasha
Ghulam, Unzela
author_sort Hina, Ayesha
collection PubMed
description Introduction: Cutaneous adverse drug reactions (CADRs) are the most common adverse drug reactions reported in the literature. CADRs have resulted in disabling infirmities during hospitalization and complications following outdoor drug therapy. The pattern of CADRs and the responsible drugs usually changes with the introduction of newer drugs and evolving clinical practices. Moreover, several international studies showed variable prevalence, emphasizing the need for local data in light of different socioeconomic and demographic practices. Therefore, the purpose of this study is to evaluate the prevalence of adverse cutaneous drug reactions and identify the clinical spectrum and any potential risk factors. Methodology: The current study is a descriptive cross-sectional study conducted at Aga Khan University Hospital, Pakistan. One hundred ninety-three patients who met the study inclusion criteria were included. Data were collected from patients on a proforma after taking informed consent. Quantitative data were presented as simple descriptive statistics giving mean and standard deviation, while qualitative variables were presented as frequency and percentages. Effect modifiers were controlled through stratification to highlight the effect of these on the outcome variable. The post-stratification chi-square test was applied and the p-value of ≤0.05 was statistically significant. Results: A total of 193 patients who had cutaneous adverse drug reactions were included in the study. The mean age in this study was 47.78±8.33 years. One hundred eight (56%) were male and 85 (44%) were female. Out of 193 patients, 135 (69.9%), 50 (25.9%), 24 (12.4%), 12 (6.2%), 20 (10.4%), 11 (5.7%) and six (3.1%) had maculopapular rash, acneiform eruptions, Stevens-Johnson syndrome, erythema multiform, urticaria, fixed drug eruptions and toxic epidermal necrolysis, respectively. Conclusion: CADRs are a common clinical presentation and awareness and knowledge about their diagnosis and prevention is important. It can be assumed that in our local setup, the clinical trends and medications causing ADRs are strikingly similar to those found in other countries. Physicians commonly come across these cases and they should be well aware of the clinical spectrum of skin reactions to enable early diagnosis and management. 
format Online
Article
Text
id pubmed-8133508
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-81335082021-05-21 Prevalence of Clinical Spectrum of Cutaneous Adverse Drug Reactions in Patients Presenting at a Tertiary Care Hospital in Pakistan Hina, Ayesha Masood, Sadia Jamil, Sajjad Tabassum, Saadia Jalil, Palwasha Ghulam, Unzela Cureus Dermatology Introduction: Cutaneous adverse drug reactions (CADRs) are the most common adverse drug reactions reported in the literature. CADRs have resulted in disabling infirmities during hospitalization and complications following outdoor drug therapy. The pattern of CADRs and the responsible drugs usually changes with the introduction of newer drugs and evolving clinical practices. Moreover, several international studies showed variable prevalence, emphasizing the need for local data in light of different socioeconomic and demographic practices. Therefore, the purpose of this study is to evaluate the prevalence of adverse cutaneous drug reactions and identify the clinical spectrum and any potential risk factors. Methodology: The current study is a descriptive cross-sectional study conducted at Aga Khan University Hospital, Pakistan. One hundred ninety-three patients who met the study inclusion criteria were included. Data were collected from patients on a proforma after taking informed consent. Quantitative data were presented as simple descriptive statistics giving mean and standard deviation, while qualitative variables were presented as frequency and percentages. Effect modifiers were controlled through stratification to highlight the effect of these on the outcome variable. The post-stratification chi-square test was applied and the p-value of ≤0.05 was statistically significant. Results: A total of 193 patients who had cutaneous adverse drug reactions were included in the study. The mean age in this study was 47.78±8.33 years. One hundred eight (56%) were male and 85 (44%) were female. Out of 193 patients, 135 (69.9%), 50 (25.9%), 24 (12.4%), 12 (6.2%), 20 (10.4%), 11 (5.7%) and six (3.1%) had maculopapular rash, acneiform eruptions, Stevens-Johnson syndrome, erythema multiform, urticaria, fixed drug eruptions and toxic epidermal necrolysis, respectively. Conclusion: CADRs are a common clinical presentation and awareness and knowledge about their diagnosis and prevention is important. It can be assumed that in our local setup, the clinical trends and medications causing ADRs are strikingly similar to those found in other countries. Physicians commonly come across these cases and they should be well aware of the clinical spectrum of skin reactions to enable early diagnosis and management.  Cureus 2021-04-19 /pmc/articles/PMC8133508/ /pubmed/34026384 http://dx.doi.org/10.7759/cureus.14568 Text en Copyright © 2021, Hina et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Dermatology
Hina, Ayesha
Masood, Sadia
Jamil, Sajjad
Tabassum, Saadia
Jalil, Palwasha
Ghulam, Unzela
Prevalence of Clinical Spectrum of Cutaneous Adverse Drug Reactions in Patients Presenting at a Tertiary Care Hospital in Pakistan
title Prevalence of Clinical Spectrum of Cutaneous Adverse Drug Reactions in Patients Presenting at a Tertiary Care Hospital in Pakistan
title_full Prevalence of Clinical Spectrum of Cutaneous Adverse Drug Reactions in Patients Presenting at a Tertiary Care Hospital in Pakistan
title_fullStr Prevalence of Clinical Spectrum of Cutaneous Adverse Drug Reactions in Patients Presenting at a Tertiary Care Hospital in Pakistan
title_full_unstemmed Prevalence of Clinical Spectrum of Cutaneous Adverse Drug Reactions in Patients Presenting at a Tertiary Care Hospital in Pakistan
title_short Prevalence of Clinical Spectrum of Cutaneous Adverse Drug Reactions in Patients Presenting at a Tertiary Care Hospital in Pakistan
title_sort prevalence of clinical spectrum of cutaneous adverse drug reactions in patients presenting at a tertiary care hospital in pakistan
topic Dermatology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8133508/
https://www.ncbi.nlm.nih.gov/pubmed/34026384
http://dx.doi.org/10.7759/cureus.14568
work_keys_str_mv AT hinaayesha prevalenceofclinicalspectrumofcutaneousadversedrugreactionsinpatientspresentingatatertiarycarehospitalinpakistan
AT masoodsadia prevalenceofclinicalspectrumofcutaneousadversedrugreactionsinpatientspresentingatatertiarycarehospitalinpakistan
AT jamilsajjad prevalenceofclinicalspectrumofcutaneousadversedrugreactionsinpatientspresentingatatertiarycarehospitalinpakistan
AT tabassumsaadia prevalenceofclinicalspectrumofcutaneousadversedrugreactionsinpatientspresentingatatertiarycarehospitalinpakistan
AT jalilpalwasha prevalenceofclinicalspectrumofcutaneousadversedrugreactionsinpatientspresentingatatertiarycarehospitalinpakistan
AT ghulamunzela prevalenceofclinicalspectrumofcutaneousadversedrugreactionsinpatientspresentingatatertiarycarehospitalinpakistan